CO2023015915A2 - Anticuerpos anti-ccr8 - Google Patents

Anticuerpos anti-ccr8

Info

Publication number
CO2023015915A2
CO2023015915A2 CONC2023/0015915A CO2023015915A CO2023015915A2 CO 2023015915 A2 CO2023015915 A2 CO 2023015915A2 CO 2023015915 A CO2023015915 A CO 2023015915A CO 2023015915 A2 CO2023015915 A2 CO 2023015915A2
Authority
CO
Colombia
Prior art keywords
antibodies
ccr8
ccr8 antibodies
methods
present disclosure
Prior art date
Application number
CONC2023/0015915A
Other languages
English (en)
Inventor
Andrew J Mccluskey
Paustian Amanda M Schmidt
Jane Seagal
Julie L Wilsbacher
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CO2023015915A2 publication Critical patent/CO2023015915A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente descripción proporciona anticuerpos anti-CCR8, que incluyen composiciones y métodos para usar tales anticuerpos.
CONC2023/0015915A 2021-07-27 2023-11-22 Anticuerpos anti-ccr8 CO2023015915A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
PCT/US2022/074214 WO2023010054A1 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Publications (1)

Publication Number Publication Date
CO2023015915A2 true CO2023015915A2 (es) 2023-12-11

Family

ID=82898810

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0015915A CO2023015915A2 (es) 2021-07-27 2023-11-22 Anticuerpos anti-ccr8

Country Status (12)

Country Link
US (1) US11639393B2 (es)
EP (1) EP4214240A1 (es)
JP (1) JP2023018678A (es)
CN (1) CN117425677A (es)
AR (1) AR126578A1 (es)
AU (1) AU2022317803A1 (es)
BR (1) BR112023024837A2 (es)
CA (1) CA3220121A1 (es)
CO (1) CO2023015915A2 (es)
IL (1) IL307533A (es)
TW (1) TW202321304A (es)
WO (1) WO2023010054A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
MX2018013952A (es) 2016-05-16 2019-06-24 Checkmab S R L Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores.
WO2018112033A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs
DK3616720T3 (da) 2017-03-29 2021-03-29 Shionogi & Co Farmaceutisk sammensætning til cancerbehandling
MX2021007576A (es) 2018-12-27 2021-08-24 Shionogi & Co Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8).
MX2022008341A (es) 2020-01-06 2022-08-10 Vaccinex Inc Anticuerpos anti-ccr8 y usos de estos.
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
WO2021178749A2 (en) 2020-03-05 2021-09-10 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
PE20230821A1 (es) 2020-03-23 2023-05-19 Bristol Myers Squibb Co Anticuerpos anti-ccr8 para el tratamiento del cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
CA3190879A1 (en) 2020-08-28 2022-03-03 Shuang LU Ccr8 antibody and application thereof
WO2022081718A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4010378A4 (en) 2020-10-16 2023-07-26 LaNova Medicines Limited ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
EP4267618A1 (en) 2020-12-24 2023-11-01 Vib Vzw Non-blocking human ccr8 binders

Also Published As

Publication number Publication date
US11639393B2 (en) 2023-05-02
BR112023024837A2 (pt) 2024-02-20
WO2023010054A1 (en) 2023-02-02
AU2022317803A1 (en) 2023-10-26
JP2023018678A (ja) 2023-02-08
AR126578A1 (es) 2023-10-25
CN117425677A (zh) 2024-01-19
EP4214240A1 (en) 2023-07-26
CA3220121A1 (en) 2023-02-02
IL307533A (en) 2023-12-01
TW202321304A (zh) 2023-06-01
US20230048553A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
CO2021002907A2 (es) Constructos de anticuerpos para cldn18.2 y cd3
CL2022002771A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y su uso (divisional de cl 201703195).
BR112019012342A2 (pt) anticorpos il-11
BR112019012343A2 (pt) anticorpos il-11ra
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2020001543A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de los mismos.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CO2023015915A2 (es) Anticuerpos anti-ccr8
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
AR119677A1 (es) Dominios de unión anti-cd38
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
UY39743A (es) Conjugados de anticuerpo anti-c-met y fármaco
CO2019013718A2 (es) Anticuerpos anti-trkb
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3